The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Hearing-Related Quality of Life
Key facts
- Where
- Turku, FinlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06551857, who can take part
Where in Finland
- Turku University HospitalTurku, FinlandContact: Tytti Willberg, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Turku University Hospital
- Trial code
- NCT06551857EU 2024-513437-21-00
- Record updated
- 16 April 2025
- Original description
The study will assess the effect of cancer treatments on speech perception in noise, cognition, and hearing-related quality of life by monitoring 200 cancer patients receiving standard care for their underlying malignancy.Read full original descriptionShow less
The study will assess the effect of cancer treatments on speech perception in noise, cognition, and hearing-related quality of life by monitoring 200 cancer patients receiving standard care for their underlying malignancy.
Inclusion: written informed consent; native Finnish speaker; age-normative hearing; for participants in the treatment arms: diagnosis of a malignancy that will be treated with curative intent with any of the following: 1) Cisplatin as the main chemotherapeutic agent, 2) oxaliplatin as the main chemotherapeutic agent, 3) cisplatin-based chemoradiation therapy in the head and neck region, 4) radiation therapy in the head and neck region.
Exclusion: Current or prior major otological condition that has affected or has had the potential to affect hearing; Prior use of ototoxic medications; Prior malignancy treated with chemotherapeutics or radiation therapy; Any significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk by participation in the trial, or may influence the result of the trial; Any condition that, in the opinion of the investigator, would interfere with adherence to the trial requirements; For participants in the treatment arms:; Allergy or hypersensitivity to trial medications or their ingredients; inability to provide written informed consent; Conductive or asymmetric sensorineural HL of any severity; Severe sensorineural HL; Pregnancy or breast-feeding, aim of becoming pregnant during the trial.